We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Tilray's business has gotten bigger over the years, but it continues to struggle with achieving profitability.
Recently, Zacks.com users have been paying close attention to Tilray Brands (TLRY). This makes it worthwhile to examine what the stock has in store.
Or is it just a value trap?
SNDL faces pressure after Q1 results show falling sales, weak cannabis demand, and margin strain, raising concerns about growth in a saturated Canadian market.
Most regulatory headwinds remain for cannabis companies like Tilray.
Marijuana rescheduling may have taken place in the U.S., but that doesn't mean legalization will happen anytime soon.
Tilray Brands, Inc. (NASDAQ:TLRY) is one of the 7 Best Hemp Stocks To Buy Now. On April 22, Bloomberg reported, citing an on-air discussion with CEO Irwin Simon, that Tilray Brands, Inc. (NASDAQ:TLRY) shares rose by around 10% after surging as much as 18% earlier, amid strong trading activity of more than 20 million shares. […]
Tilray doesn't fit squarely into the value trap or value stock categories.
Tilray Brands (TLRY) surged in premarket trading on fresh enthusiasm over marijuana rescheduling, then gave back much of the move as the session unfolded. The early excitement followed a U.S. government shift to reclassify certain marijuana products and a market rush into cannabis names. By later ...
The Trump administration also announced the beginning of an expedited administrative hearing process to consider the rescheduling marijuana more broadly.